Elevated PSA Can Lead to Far Too Many Unnecessary Prostate Biopsies

Let's Make it Zero

The Prostate Health Index (​phi ) Can Reduce Unnecessary Biopsies

The Prostate Health Index is an FDA approved blood test that can help differentiate prostate cancer from benign conditions in men with elevated PSA. 

• phi combines total PSA, free PSA, and pro2PSA via a sophisticated algorithm, into a single score.
• a phi score of less than 27 indicates a higher likelihood of a benign condition.
• a phi score that is greater than 36 indicates the increased possibility of prostate cancer.

Download Brochure

​​​Physicians

If you are physician, click the Order Test button below to begin offering this test to patients in your practice. 

ORDER TEST

​​​Patients                

Download our Patient Physician Discussion Guide to take to your next appointment.
​ 

Download Guide

Order               

You can also initiate an order through our physician network clicking the patient ordering button or calling 855-420-7140

Patient OrderIng

Prostate Health Index Patient Selection Criteria

Male patients may be a candidate for the Prostate Index Test if they are age 50 years and older with an elevated PSA between 4ng/ml and 10ng/ml. Peer-reviewed published studies support the use of Prostate Health Index in men with total PSA values as low as 2 ng/ml (1-4)

The Prostate Health Index is included in the National Comprehensive Cancer Network (NCCN) Guideline for Prostate Cancer Early Detection as a blood test to improve specificity for prostate cancer detection. (5)

Contact Us

Fill out my online form

Client Services

You can reach client services directly at 
1-855-420-7140

Email Client Services

References​

1. Catalona WJ, Partin AW, Sanda MG, et al. A Multi-Center Study of [−2]Pro-Prostate-Specific Antigen (PSA) in Combination with PSA and Free PSA for Prostate Cancer Detection in the 2.0 to 10.0 ng/mL PSA Range. The Journal of Urology. 2011;185(5):1650-1655. 
2. Loeb S, Sanda MG, Broyles DL, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. The Journal of Urology. 2015;193(4):1163-1169 
3. Huang YQ, Sun T, Zhong WD, et al. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol  2014;2(4):343-350 
4. Lepor A, Catalona WJ, Loeb S. The Prostate Health Index: Its Utility In Prostate Cancer Detection. The Urologic Clinics of North America. 2016;43(1):1-6. 
5. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2018 – April 5, 2018